1. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
by Keyur P. Patel, Kate J. Newberry, Rajyalakshmi Luthra, Elias Jabbour, Sherry Pierce, Jorge Cortes, Rajesh Singh, Meenakshi Mehrotra, Mark J. Routbort, Madan Luthra, Taghi Manshouri, Fabio P. Santos, Hagop Kantarjian, and Srdan Verstovsek
Blood
Volume 126(6):
August 6, 2015
©2015 by American Society of Hematology

2. Frequency and distribution of mutations.
Frequency and distribution of mutations. (A) Circos plot showing the frequency of co-occurring mutations.11 Length of the arc corresponds to the frequency of mutations, whereas the width of the ribbons between 2 genes shows the frequency of co-occurrence. (B) Frequency of mutations by disease subtype. (C) Plot of mutations by case.
Keyur P. Patel et al. Blood 2015;126:
©2015 by American Society of Hematology

3. Kaplan-Meier analysis of time to event outcomes.
Kaplan-Meier analysis of time to event outcomes. Time to treatment failure stratified by (A) molecular risk group and (B) number of mutations.
Keyur P. Patel et al. Blood 2015;126:
©2015 by American Society of Hematology